1/62
Looks like no tags are added yet.
Pacerone, Cordarone
Amiodarone Hydrochloride
Main Indication: Antiarrhythmic
Therapeutic Classification: Antiarrhythmic
FDA Labeled Indication:
1. Afib
2. Supraventricular arrhythmia
3. Afib, pharmacologic cardioversion
4. Maintenance of sinus rhythm, afib
5. Rate control, afib
MOA: Type III antiarrhythmic that prolongs the effective refractory period of atrial and ventricular tissue by blocking potassium conductance.
Box Warnings: Arrhythmias, hepatotoxicity, proarrhythmic effects, pulmonary toxicity
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Nausea, vomiting, phospholipidemia
Key Patient Counseling Points:
- Use sunscreen; avoid tanning beds and prolonged sun exposure
- Report signs/symptoms of cardiac arrhythmias, pulmonary toxicity, or liver toxicity
- Multiple drug interactions so inform providers about all medications you are taking
- Take consistently with regard to meals but avoid taking with grapefruit or grapefruit juice
A patient medication guide must be dispensed with this medication
Apresoline
Hydralazine Hydrochloride
Main Indication: Antihypertensive
Therapeutic Classification: Peripheral Vasodilator
FDA Labeled Indication:
HTN
MOA: A vasodilator that reduces total peripheral resistance by direct action on vascular smooth muscle, with an effect greater on arterioles than on veins
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): None known
Key Patient Counseling Points:
- Hydralazine is not a first-line therapy for HTN.
- Hydralazine may cause drug-induced lupus erythematosus (DILE) and has a higher incidence compared to other drugs associated with DILE.
- Thiazide diuretics, calcium channel blockers, ACEIs, and ARBs are preferred.
- Hydralazine may be beneficial in patients intolerant of ACEIs or ARBs and when added ACEIs or ARBs in African Americans.
- Commonly used off-label in conjunction with nitrates in various subgroups of patients with systolic heart failure.
- Injectable formulation also available.
Norvasc
Amlodipine
Main Indication: Antihypertensive
Therapeutic Classification: Calcium Channel Blocker
FDA Labeled Indication:
- HTN
- Stable angina
- Vasospastic angina
MOA:
Long-acting dihydropyridine calcium-channel-blocking drug with potent arterial and coronary vasodilating properties
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Peripheral edema, pulmonary edema
Key Patient Counseling Points:
- Instruct patient to report signs/symptoms of hypotension or exacerbation of angina with initial dosing and dose changes
- Avoid alcohol while taking the drug
- Report signs/symptoms of peripheral edema, fatigue, hypotension, or hepatic dysfunction
- This medicine may cause dizziness
- Avoid activities that could be dangerous if dizziness occurs at the initiation of therapy
- Dizziness may be worse if too much water is lost from the body due to excessive sweating, diarrhea, or vomiting.
Cardizem, Cartia, Dilacor, Dilt-XR, Tiazac
Diltiazem Hydrochloride
Main Indication: Antihypertensive
Therapeutic Classification: Calcium Channel Blocker
FDA Labeled Indication:
- HTN
- Stable, chronic angina
- Atrial arrhythmia and paroxysmal supraventricular tachycardia
MOA:
A calcium-channel-blocking drug that decreases HR, prolongs AV nodal conduction, and decreases arteriolar and coronary vascular tone. It also has negative inotropic properties
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Edema
- Headache
Key Patient Counseling Points:
- Report symptomatic hypotension, bradyarrhythmia, peripheral edema, or syncope
- This drug is available in multiple brand names with varying properties by brand.
- Instruct patient to follow administration instructions specific to the prescribed brand with regard to meals and timing.
- Do not drink alcohol while taking this drug.
- Some products may be opened and sprinkled on a spoonful of applesauce (applesauce should not be hot, and should be swallowed without chewing, followed by a glass of water).
- Administer at same time of day, either morning or evening.
Procardia (XL), Nifedical XL, Adalat CC
Nifedipine
Main Indication: Antihypertensive/antianginal
Therapeutic Classification: Dihydropyridine Calcium Channel Blocker
FDA Labeled Indication:
- HTN
- Stable angina
- Variant angina
MOA:
A calcium ion influx inhibitor that selectively inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle. Nifedipine does not alter serum calcium concentrations.
Box Warnings: None
Briggs Pregnancy Recommendation: None
Common AEs (>10%): Flushing, headache, dizziness, weakness, nausea, dyspepsia
Key Patient Counseling Points:
- Take Adalat CC on an empty stomach.
= Report signs/symptoms of hypotension, exacerbation of angina, peripheral edema, fatigue, or hypotension.
- Avoid sudden discontinuation of drug as this may cause rebound HTN.
- May cause dizziness; avoid driving or using hazardous machinery until effects are known.
- Avoid grapefruit juice.
- May see tablet or shell of dosage form in stool.
Isoptin, Calan, Verelan
Verapamil Hydrochloride
Main Indication: Antihypertensive/antianginal
Therapeutic Classification: Calcium Channel Blocker
FDA Labeled Indication:
- Angina
- Atrial arrhythmia or paroxysmal supraventricular tachycardia prophylaxis
- HTN
MOA:
Inhibits calcium “slow channels” on vascular smooth muscle and myocardium producing relaxation of muscle and vasodilation. Increases myocardial oxygen delivery and slow conduction through the AV node
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Gingival hyperplasia (your gums overgrown)
Key Patient Counseling Points:
- Do not crush or chew extended-release products. Contents of extended-release capsules may be sprinkled on food and swallowed without chewing, followed by water.
- Report symptomatic hypotension, bradyarrhythmia, peripheral edema, or syncope.
- Avoid sudden discontinuation of drug, as this may precipitate hypertensive rebound/crisis. Rise slowly from a sitting or lying position to avoid dizziness.
- Avoid alcohol and grapefruit juice.
- Calcium channel blockers are not drugs of first choice for hypertension, but may be used in combination with other agents in patients with inadequate blood pressure response.time of day, either morning or evening.
Tenormin
Atenolol
Main Indication: Antihypertensive
Therapeutic Classification: Beta Blocker
FDA Labeled Indication:
- Angina pectoris
- HTN
- AMI (acute myocardial infarction)
MOA:
A cardioselective β-adrenergic that decreases AV nodal conduction in supraventricular tachycardias and blockade of catecholamine-induced dysrhythmias
Box Warnings: Avoid abrupt withdrawal
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Bradyarrhythmias
- Cold extremities
- Dizziness, fatigue
- Hypotension
- Depression
Key Patient Counseling Points:
- Take on an empty stomach
- Avoid abrupt discontinuation; exacerbations of angina may occur
- Report signs/symptoms of bradycardia, hypotension, heart failure, or exacerbation of angina with initial dosing and dose changes
- May cause dizziness or drowsiness
- Diabetic patients to carefully follow blood sugar levels as β-blockers may mask symptoms of hypoglycemia
- Drug may cause sexual side effects, fatigue, and depression
Coreg, Coreg CR
Carvedilol
Main Indication: Antihypertensive
Therapeutic Classification: Beta Blocker
FDA Labeled Indication:
- Heart failure with reduced ejection fraction
- HTN
- Impaired left ventricular function post-MI
MOA: A selective α1- and nonselective β-adrenergic blocker that decreases AV nodal conduction in supraventricular tachycardias and blockade of catecholamine-induced dysrhythmia
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Cold extremities
- Dizziness
- Erectile dysfunction
- Fatigue
- Hypotension
- Weight gain
Key Patient Counseling Points:
- Take carvedilol with food or milk
- Report signs/symptoms of heart failure, bradyarrhythmias, bronchospasm, hypotension, syncope, or exacerbation of angina with initial dosing and dose changes.
- Avoid abrupt discontinuation, may cause rebound HTN
- Avoid driving, using machinery, or doing anything else that could be dangerous if not alert
- Diabetic patients should carefully follow blood sugar levels as beta-blockers may mask symptoms of hypoglycemia
Lopressor (Tartrate)
Toprol-XL (Succinate)
Metoprolol
Main Indication: Antihypertensive
Therapeutic Classification: Beta-Adrenergic Blocker
FDA Labeled Indication:
1. Angina
2. Heart failure with reduced ejection fraction
3. HTN
4. AMI
MOA: A cardioselective β-adrenergic blocker used in arrhythmias, HTN, angina pectoris, and heart failure. It is also effective in decreasing post-MI mortality.
Box Warnings: Ischemic heart disease with abrupt withdrawal
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Dizziness,
- Fatigue
- Hypotension
Key Patient Counseling Points:
- Take on an empty stomach and avoid alcohol
- Avoid abrupt discontinuation, exacerbations of angina may occur
- Instruct patients to report signs/symptoms of hypotension, heart failure, or exacerbation of angina with initial dosing and dose changes
- Advise diabetic patients to carefully follow blood sugar levels as beta-blockers may mask symptoms of hypoglycemia
Bystolic
Nebivolol Hydrochloride
Main Indication: Antihypertensive
Therapeutic Classification: Beta-Adrenergic Blocker (B1 Selective)
FDA Labeled Indication:
1. HTN
MOA: A long-acting cardioselective β1-adrenoceptor antagonist without intrinsic sympathomimetic activities. The mechanism of action of the antihypertensive response of nebivolol is not fully understood. Possible mechanisms include decreased HR, decreased myocardial contractility and vasodilation, and decreased peripheral vascular resistance
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): None Known
Key Patient Counseling Points:
- Report signs/symptoms of hypotension, worsening heart failure, or bronchospastic disease
- Diabetic patients should carefully monitor blood sugar levels as beta-blockers may mask symptoms of hypoglycemia
- Do not discontinue drug abruptly, as this may cause rebound angina or, in some cases, AMI.
Inderal (LA), Innopran XL
Propranolol Hydrochloride
Main Indication: Antihypertensive
Therapeutic Classification: Beta-Adrenergic Blocker (Non-Selective)
FDA Labeled Indication:
1. Angina pectoris, chronic:
2. Cardiac dysrhythmia
3. HTN
4. Migraine, prophylaxis
MOA: A nonselective β-adrenergic blocker that competitively blocks β1 and β2 receptors, thereby preventing β-adrenergic stimulation. The mechanism of its antihypertensive and antimigraine effects is not completely understood.
Box Warnings: None
Briggs Pregnancy Recommendation: Human data suggest risk in 2nd and 3rd trimesters
Common AEs (>10%): Hypotension
Key Patient Counseling Points:
- Take immediate-release tablets on an empty stomach
- ER can be taken with or without food but administer consistently with respect to food
- Avoid alcohol
- Avoid abrupt discontinuation; exacerbations of angina may occur
- Report signs/symptoms of hypotension, CHF, or exacerbation of angina with initial dosing and dose changes
- This medicine may cause dizziness
- Diabetic patients should carefully follow blood glucose as beta-blockers may mask symptoms of hypoglycemia.
Normodyne
Labetalol
Main Indication: Antihypertensive
Therapeutic Classification: α/β Adrenergic Blocker
FDA Labeled Indication:
1. HTN
Dosage Form (How Supplied): Tablet
MOA: An adrenergic receptor blocking drug that has selective α1- and nonselective β-adrenergic receptor blocking actions
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Dizziness
- Fatigue
- Nausea
Key Patient Counseling Points:
- Report signs/symptoms of hypotension with initial dosing and dose changes
- Avoid alcohol while taking drug
- May cause dizziness
- Instruct patient to rise slowly from a sitting/supine position, as labetalol may cause orthostatic hypotension. - Report signs/symptoms of bronchospasm, slow HR, hepatotoxicity, or syncope
- Advise diabetic patients to carefully follow blood sugar levels as beta-blockers may mask symptoms of hypoglycemia
- Advise patients against sudden discontinuation of drug as this may cause rebound HTN
Lotensin
Benazepril Hydrochloride
Main Indication: Antihypertensive
Therapeutic Classification: ACE Inhibitor
FDA Labeled Indication:
- HTN
MOA: A competitive ACE-I. It also reduces serum aldosterone, leading to decreased sodium retention, potentiates the vasodilator kallikrein–kinin system, and can alter prostanoid metabolism, inhibit the sympathetic nervous system, and inhibit the tissue renin-angiotensin system
Box Warnings: Pregnancy, fetal toxicity
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): None known
Key Patient Counseling Points:
- Avoid pregnancy
- Seek medical attention immediately if you experience any facial swelling
- Most common adverse effect is dry cough
- Use potassium supplements or salt substitutes only under medical supervision
- May cause dizziness that may worsen if dehydrated.
- Take at the same time daily
Vasotec, Epaned
Enalapril Maleate
Main Indication: Antihypertensive
Therapeutic Classification: ACE Inhibitor, Antihypertensive
FDA Labeled Indication:
1. Heart failure
2. HTN
3. kidney disease, nondiabetic
MOA: A prodrug that is rapidly converted to its active metabolite, enalaprilat, a competitive ACEI. It reduces serum aldosterone, leading to decreased sodium retention, potentiates the vasodilator kallikrein–kinin system, and inhibits the sympathetic nervous system and tissue renin-angiotensin system. The net effect is reduction in total peripheral resistance and BP in hypertensive patients and reduction in elevated afterload in patients with heart failure.
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): Increased SCr
Key Patient Counseling Points:
- Use potassium supplements or salt substitutes only under medical supervision
- Report signs/symptoms of angioedema
- May cause dizziness that may worsen if dehydrated
- Use caution rising from sitting or lying position, especially when initiating treatment.
Prinivil, Zestril
Lisinopril
Main Indication: Antihypertensive
Therapeutic Classification: ACE Inhibitor
FDA Labeled Indication:
1. ST-segment elevation MI
2. Heart failure with reduced ejection fraction
2. HTN
MOA: A competitive ACEI. It also reduces serum aldosterone, leading to decreased sodium retention, potentiates the vasodilator kallikrein–kinin system, and can alter prostanoid metabolism, inhibit the sympathetic nervous system, and inhibit the tissue renin-angiotensin system.
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): None known
Key Patient Counseling Points:
- Avoid pregnancy
- Use potassium supplements or salt substitutes only under medical supervision
- May cause dizziness that may worsen if dehydrated.
Altace
Ramipril
Main Indication: Antihypertensive
Therapeutic Classification: ACE Inhibitor
FDA Labeled Indication:
1. HF post-MI
2. HTN
3. Reduce risk of myocardial infarction, stroke, and death from cardiovascular causes
MOA: A competitive ACEI. It is also a prodrug for the more potent ACEI ramiprilat. ACEI prevents conversion of angiotensin I to angiotensin II (a vasoconstrictor). It also reduces serum aldosterone, leading to decreased sodium retention, potentiates the vasodilator kallikrein–kinin system, and inhibits the tissue renin-angiotensin system.
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): None known
Key Patient Counseling Points:
- Avoid pregnancy
- Use potassium supplements or salt substitutes only under medical supervision
- May cause dizziness that may worsen if dehydrated.
Prazin; Minipress; Prazo
Prazosin
Main Indication: Antihypertensive
Therapeutic Classification:
α1-Adrenergic Receptor Antagonist
FDA Labeled Indication:
HTN
MOA:
Causes peripheral vasodilation by selective, competitive inhibition of vascular postsynaptic alpha 1-adrenergic receptors, thus reducing peripheral vascular resistance and blood pressure.
Box Warnings: None
Briggs Pregnancy Recommendation: None
Common AEs (>10%):
- Postural hypotension
- Dizziness
Key Patient Counseling Points:
- This medication can cause low blood pressure, dizziness, feeling faint or lightheaded, blurry vision.
- Drowsiness or dizziness are more likely to occur after the first dose or after an increase in dose.
- Do not drive, use machinery, or do anything that needs mental alertness until you know how this medication affects you.
- Do not stand or sit up quickly, especially if you are an older patient.
- Avoid alcohol.
- This medication may cause your mouth to get dry, chewing sugarless gum or sucking on hard candy and drinking water may help.
- Males should report an erection that last longer than 4 hours or if it becomes painful. It may be a sign of a serious problem and must be treated right away to prevent permanent damage.
Catapres, Kapvay
Clonidine
Main Indication: Antihypertensive
Therapeutic Classification: α2-Adrenergic Agonist
FDA Labeled Indication:
- ADHD
- HTN
MOA:
Clonidine stimulates presynaptic α2-adrenergic receptors and blocks postsynaptic α2-adrenergic receptors in the CNS by activating inhibitory neurons to decrease sympathetic outflow. Clonidine is not a complete agonist, so some of its effects might result from antagonist actions at presynaptic α-receptors. These actions reduce peripheral vascular resistance, renal vascular resistance, HR, and BP
Box Warnings: Epidermal Use
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Feeling nervous
- Headache
- Somnolence
- Erythema (patchy)
- Xerostomia (dry mouth)
Key Patient Counseling Points:
- Avoid alcohol, CNS depressants.
- Use caution with driving and other tasks requiring alertness. - May cause nausea, vomiting, insomnia, constipation, fatigue, or dry mouth.
- Swallow extended-release tablet whole.
- Apply patch to hairless area of intact skin on upper outer arm or chest; rotate patch location.
- If patch loosens during the 7-d wearing, secure adhesive cover.
- Report signs/symptoms of hypotension, exacerbation of angina, peripheral edema, fatigue, hypotension, or hepatic dysfunction with initial dosing and dose changes.
- Avoid abrupt discontinuation to avoid rebound HTN
Intuniv
Guanfacine
Main Indication: Antihypertensive/Antipsychotic
Therapeutic Classification:
α2-Adrenergic Agonist
FDA Labeled Indication:
- ADHD
- HTN
Dosage Form (How Supplied):
Tablet; ER Tablet
MOA: Stimulates postsynaptic α2-adrenergic receptors in the CNS by activating inhibitory neurons to decrease sympathetic outflow.
Box Warnings: None
Briggs Pregnancy Recommendation: Limited human data—animal data suggest low risk
Common AEs (>10%):
- Drowsiness
- Headache
- Dizziness
- Insomnia
- Anorexia
Key Patient Counseling Points:
- Avoid alcohol, CNS depressants
- Caution with driving and other tasks requiring alertness. - Swallow extended-release tablet whole, may be taken with or without food.
- Report signs/symptoms of hypotension, exacerbation of angina peripheral edema, fatigue, hypotension, or hepatic dysfunction with initial dosing and dose changes.
- Avoid abrupt discontinuation to reduce risk of rebound HTN
Eliquis
Apixaban
Main Indication: Anticoagulant
Therapeutic Classification: Factor Xa Inhibitor
FDA Labeled Indication:
1. Afib, nonvalvular
2. Hip or knee replacement surgery
3. DVT or PE treatment
MOA: A selective inhibitor of factor Xa. By inhibiting factor Xa, apixaban decreases thrombin generation and thrombus development.
Box Warnings: Premature discontinuation increases risk of thrombotic events; increased risk of spinal hematoma with spinal puncture or neuraxial anesthesia
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
Bleeding
Key Patient Counseling Points:
- Seek medical attention if any unexpected bleeding or trouble breathing.
- Take with or without food.
- Do not stop taking apixaban without talking with your HCP; stopping early may increase the risk of stroke, especially in patients with atrial fibrillation.
- Apixaban should be interrupted 24-48 h prior to dental and surgical procedures and re-started after hemostasis.
- Avoid OTC NSAIDs and high-dose aspirin; they increase the risk of bleeding.
Xarelto
Rivaroxaban
Main Indication: Anticoagulant
Therapeutic Classification: Factor Xa Inhibitor
FDA Labeled Indication:
1. Prevention of thromboembolism in patients after orthopedic surgery
2. Prevention of thromboembolism in patients with nonvalvular atrial fibrillation
3. Treatment and secondary prevention of DVT or pulmonary embolism
4. Coronary artery disease (stable) or peripheral artery disease
MOA: An orally bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require a cofactor (such as antithrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation.
Box Warnings: Premature discontinuation increases thrombotic risk, risk of spinal/epidural hematoma
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Bleeding
Key Patient Counseling Points:
- Educate patient on signs and symptoms of bleeding and interactions with other anticoagulant or antiplatelet medications, including OTC medications
- Warn of risks of epidural (spinal) anesthesia while taking rivaroxaban
- Doses ≥15 mg should be taken with food
- If taking for nonvalvular atrial fibrillation, take with evening meal
Coumadin, Jantoven
Warfarin
Main Indication: Anticoagulant
Therapeutic Classification: Vitamin K Antagonist
FDA Labeled Indication: Multiple FDA-labeled indications, all dosed similarly, including:
- Atrial fibrillation
- Myocardial infarction
- Prosthetic cardiac valve component embolism
- Pulmonary embolism
- Thrombosis
- Post-myocardial infarction
- Venous thromboembolism
MOA: Warfarin prevents the conversion of vitamin K back to its active form from vitamin K epoxide. This impairs formation of the vitamin K–dependent clotting factors II, VII, IX, and X (prothrombin) and proteins C and S (physiologic anticoagulants).
Box Warnings: Bleeding
Briggs Pregnancy Recommendation: Contraindicated—1st trimester
Common AEs (>10%): Bleeding
Key Patient Counseling Points:
- Report signs/symptoms of hemorrhage, skin and tissue necrosis
- Avoid situations/activities in which cuts, bruising, or injury is likely to occur
- Many significant drug-drug interactions; consult health-care professional prior to new prescription or OTC use
- Avoid alcohol, cranberry products, and drastic changes in vitamin K consumption from diet (cruciferous vegetables)
Zetia
Ezetimibe
Main Indication: Antihyperlipidemic
Therapeutic Classification: Cholesterol Absorption Inhibitor
FDA Labeled Indication:
1. Familial hypercholesterolemia-homozygous, with atorvastatin or simvastatin
2. Mixed hyperlipidemia
3. Primary hypercholesterolemia
MOA: Localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of statins and of fenofibrate.
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): None Known
Key Patient Counseling Points:
- Take with or without food and may be taken at the same time as a concurrent statin
- In patients receiving a bile acid sequestrant concurrently, ezetimibe should be taken at least 2 h before or 4 h after the bile acid sequestrant is taken
Tricor, Lipofen
Fenofibrate
Main Indication: Antihyperlipidemic
Therapeutic Classification: PPARα activator
FDA Labeled Indication: Hypertriglyceridemia, Frederickson types 4 and 5 hyperlipidemia
MOA: Activates peroxisome proliferator-activated receptor α (PPARα), which increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity). The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Hyperhomocysteinemia
Key Patient Counseling Points:
- Fenoglide tablets and Lipofen R capsules should be given with food; others can be taken without food
- Take 1 h before or 4-6 h after a bile acid binding resins
- Products are not interchangeable
- Do not use if you have severe kidney disease or liver disease
Altoprev, Mevacor
Lovastatin
Main Indication: Antihyperlipidemic
Therapeutic Classification: HMG-CoA Reductase Inhibitor
FDA Labeled Indication:
1. Coronary atherosclerosis, hypercholesterolemia
2. Familial hypercholesterolemia, heterozygous
MOA: HMG-CoA reductase inhibitors competitively inhibit conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis.
Box Warnings: None
Briggs Pregnancy Recommendation: Contraindicated - 1st semester
Common AEs (>10%):
None known
Key Patient Counseling Points:
- Immediate-release tablets should be taken with the evening meal
- Extended-release tablets should be taken at bedtime
- Swallow extended-release tablets whole; do not chew, crush, or cut.
- Avoid alcohol, grapefruit, and grapefruit juice
- Report signs/symptoms of rhabdomyolysis, jaundice (yellowing of skin or eyes), or renal failure
- There are multiple significant drug-drug interactions with lovastatin (CYP3A4)
- Consult a HCP prior to starting any new prescription or OTC medications
- Lovastatin does not take the place of lifestyle changes (diet, exercise) to lower cholesterol levels.
Lipitor
Atorvastatin
Main Indication: Antihyperlipidemic
Therapeutic Classification: HMG-CoA Reductase Inhibitor
FDA Labeled Indication:
1. Primary and secondary prevention of atherosclerotic CV disease
2. Secondary prevention of CV events in patients with or at high risk for CAD
3. Familial hypercholesterolemia (homozygous or heterozygous)
MOA: HMG-CoA reductase inhibitors competitively inhibit the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. A compensatory increase in LDL receptors, which bind and remove circulating LDL-cholesterol, results. Production of LDL-cholesterol also can decrease because of decreased production of VLDL-cholesterol or increased VLDL; removal by LDL receptors.
Box Warnings: None
Briggs Pregnancy Recommendation: Contraindicated - 1st semester
Common AEs (>10%):
Myopathy, diarrhea, headache, nasopharyngitis
Key Patient Counseling Points:
- Avoid excessive alcohol, grapefruit, and grapefruit juice (>1 L/d) consumption while taking drug
- Atorvastatin does not take the place of lifestyle changes (diet, exercise) to lower cholesterol levels
- Notify HCP if unexplained muscle tenderness or weakness occurs
Zocor
Simvastatin
Main Indication: Antihyperlipidemic
Therapeutic Classification: HMG-CoA Reductase Inhibitor
FDA Labeled Indication:
1. Hyperlipidemia
2. Primary and secondary preventions of atherosclerotic cardiovascular disease
3. Secondary prevention of cardiovascular events
4. Familial hypercholesterolemia (homozygous)
Dosage Form (How Supplied): Tablet, Suspension
MOA: HMG-CoA reductase inhibitors competitively inhibit conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. A compensatory increase in LDL receptors, which bind and remove circulating LDL-cholesterol, results. Production of LDL-cholesterol also can decrease because of decreased production of VLDL-cholesterol or increased VLDL removal by LDL receptors.
Box Warnings: None
Briggs Pregnancy Recommendation: Contraindicated—1st trimester
Common AEs (>10%): None known
Key Patient Counseling Points:
- Avoid excessive alcohol
- There are multiple significant drug-drug interactions with simvastatin
- Consult a health-care professional prior to starting any new medications, including OTC and herbal drugs
- Simvastatin does not take the place of lifestyle changes (diet, exercise) to lower cholesterol levels.
Crestor
Rosuvastatin
Main Indication: Antihyperlipidemic
Therapeutic Classification: HMG-CoA Reductase Inhibitor
FDA Labeled Indication:
1. Hyperlipidemia
2. Disorder of cardiovascular system, primary prophylaxis, familial hypercholesterolemia, homozygous, hypertriglyceridemia, mixed dyslipidemia
MOA: HMG-CoA reductase inhibitors competitively inhibit conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. A compensatory increase in LDL receptors, which bind and remove circulating LDL-cholesterol, results. Production of LDL-cholesterol can also decrease because of decreased production of VLDL-cholesterol or increased VLDL removal by LDL receptors.
Box Warnings: None
Briggs Pregnancy Recommendation: Contraindicated—1st trimester
Common AEs (>10%): Arthralgia (joint pain}
Key Patient Counseling Points:
- Do not drink alcohol
- Rosuvastatin does not take the place of diet and exercise to lower cholesterol levels.
Pravachol
Pravastatin Sodium
Main Indication: Antihyperlipidemic
Therapeutic Classification: HMG-CoA Reductase Inhibitor
FDA Labeled Indication:
1. Cerebrovascular accident (prevention), coronary arteriosclerosis (primary or secondary prevention)
2. Familial hypercholesterolemia:
3. Hyperlipidemia
MOA: HMG-CoA reductase inhibitors competitively inhibit conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol synthesis. A compensatory increase in LDL receptors, which bind and remove circulating LDL-cholesterol, results. Production of LDL-cholesterol decreases because of decreased production of VLDL-cholesterol or increased VLDL removal by LDL receptors.
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): None Known
Key Patient Counseling Points:
- Take in the evening
- Avoid concurrent heavy alcohol use
- Pravastatin does not take the place of diet and exercise to lower cholesterol levels.
Lasix
Furosemide
Main Indication: Diuretic
Therapeutic Classification: Loop Diuretic
FDA Labeled Indication:
Edema of volume overload related to heart failure, renal failure
MOA: A loop diuretic that is actively secreted via the nonspecific organic acid transport system into the lumen of the thick ascending limb of Henle’s loop, where it decreases sodium reabsorption by competing for the chloride site on the Na+-K+-2Cl- cotransporter
Box Warnings: Fluid and electrolyte loss
Briggs Pregnancy Recommendation: Human data suggest low risk
Common AEs (>10%): Hyperuricemia
Key Patient Counseling Points:
- Avoid alcohol and NSAIDs
- Increased risk of sun-sensitivity; use sunscreen and avoid tanning
- Avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness, vertigo, or blurred vision
- Report signs/symptoms of hypotension, decreased urine output, or ototoxicity; severe skin reactions
- Eat high-potassium foods, as directed by health-care professional.
Microzide
Hydrochlorothiazide (HCTZ)
Main Indication: Diuretic
Therapeutic Classification: Thiazide Diuretic
FDA Labeled Indication:
1. Edema; adjunct
2. HTN
Dosage Form (How Supplied): Capsule, Tablet
MOA: Thiazides increase sodium and chloride excretion by interfering with their reabsorption in the cortical diluting segment of the nephron
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%):
- Hypotension
- Dizziness
- Headache
Key Patient Counseling Points
- May be taken with or without food
Take early in the day to avoid nocturia, even if taken more than once/d (eg, bid administration at 8 am and 2 pm)
- May cause dizziness
- Report signs/symptoms of hypotension
- Eat high-potassium foods during therapy.
- Avoid alcohol and using NSAIDs
Zestoretic, Prinzide
Hydrochlorothiazide; Lisinopril
Main Indication: Antihypertensive
Therapeutic Classification: Thiazide Diuretic + ACE Inhibitor Combination
FDA Labeled Indication:
- ST-segment elevation MI
- HF w/ reduced EF
- HTN
- Edema; adjunct
Dosage Form (How Supplied):
Tablet
MOA:
Thiazide Diuretic + ACE Inhibitor Combination
Box Warnings:
Pregnancy
Briggs Pregnancy Recommendation: Human data suggest risk in 2nd and 3rd trimesters
Common AEs (>10%):
- Hypotension
- Dizziness
- Headache
Key Patient Counseling Points:
- Avoid pregnancy.
- May cause dizziness that may worsen if dehydrated.
- May be taken with or without food.
- Take early in the day to avoid nocturia, even if taken more than once/d (eg, bid administration at 8 am and 2 pm).
- May cause dizziness. Report signs/symptoms of hypotension
- Avoid alcohol and using NSAIDs.
Hyzaar
Hydrochlorothiazide; Losartan Potassium
Main Indication: Antihypertensive
Therapeutic Classification: Thiazide Diuretic + Angiotensin II Receptor Antagonist Combination
FDA Labeled Indication:
1. Edema; adjunct
2. HTN
3. Reduce risk of cerebrovascular accident, in hypertensive patients with left ventricular hypertrophy; prophylaxis, diabetic nephropathy
4. Diabetic nephropathy
MOA: Thiazides increase sodium and chloride excretion by interfering with their reabsorption in the cortical diluting segment of the nephron; A selective, reversible, competitive antagonist of the angiotensin II receptor (AT1), which is responsible for the physiologic effects of angiotensin II including vasoconstriction, aldosterone secretion, sympathetic outflow, and stimulation of renal sodium reabsorption
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%):
- Hypotension
- Dizziness
- Headache
Key Patient Counseling Points
- May be taken with or without food
Take early in the day to avoid nocturia, even if taken more than once/d (eg, bid administration at 8 am and 2 pm)
- Report signs/symptoms of hypotension
- Avoid alcohol and using NSAIDs
- Avoid pregnancy
- Avoid sudden discontinuation; rebound HTN can occur - - Use potassium supplements or salt substitutes only under medical supervision
- May cause dizziness that may worsen if dehydrated
- Seek medical attention if angioedema, excessive fluid loss, hyperkalemia, reduction in urination, or jaundice occurs.
Dyazide; Maxzide
Hydrochlorothiazide; Triamterene
Main Indication: Antihypertensive
Therapeutic Classification: Thiazide Diuretic + Potassium Sparing
FDA Labeled Indication:
1. Edema
2. HTN
Dosage Form (How Supplied): Tablet
MOA: Triamterene acts directly from the distal tubular lumen on active sodium exchange for potassium and hydrogen, producing a mild diuresis that is independent of aldosterone concentration. Antihypertensive activity is inconsistent and less pronounced than with thiazides or spironolactone. Hydrochlorothiazide is a thiazide diuretic that increases sodium and chloride excretion by interfering with their reabsorption in the cortical diluting segment of the nephron; a mild diuresis of slightly concentrated urine results.
Box Warnings: Hyperkalemia
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
- Hypotension
- Dizziness
- Headache
Key Patient Counseling Points
- May cause dizziness. Rise slowly from a sitting or lying position to avoid dizziness.
- Avoid foods that are high in potassium, potassium supplements, or potassium-containing salt substitutes.
- Avoid alcohol and NSAIDs.
- May cause photosensitivity; use sunscreen.
- Use with caution in patients with sulfonamide allergy.
Hygroton, Thalitone
Chlorthalidone
Main Indication: Diuretic
Therapeutic Classification: Thiazide Diuretic
FDA Labeled Indication:
- HTN
- Edema
Dosage Form (How Supplied):
Tablet
MOA:
Chlorthalidone increases sodium and chloride excretion by interfering with their reabsorption in the cortical-diluting segment of the nephron.
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%):
- Dizziness
- Hypotension
- Hyperuricemia
Key Patient Counseling Points:
- Take in the morning with food
- Instruct patient to report signs/symptoms of dyspnea, hypotension, gout, or heart failure
- Avoid alcohol (may cause hypotension) and NSAIDs (may decrease effectiveness)
- This medicine may cause dizziness or blurred vision.
- Avoid driving, using machinery, or doing anything else that could be dangerous if not alert
Aldactone, CaroSpir
Spironolactone
Main Indication: Diuretic
Therapeutic Classification: K+ Sparing Diuretic & Selective Aldosterone Blocker
FDA Labeled Indication:
- Heart failure
- Primary aldosteronism
- HTN
- Ascites, cirrhosis of liver
MOA:
A steroidal competitive aldosterone antagonist that acts from the interstitial side of the distal and collecting tubular epithelium to block sodium-potassium exchange, producing a delayed and mild diuresis. The diuretic effect is maximal in states of hyperaldosteronism. Excretion of sodium and chloride excretion is increased; excretion of potassium and magnesium is decreased. Spironolactone has mild antihypertensive activity and has demonstrated a beneficial effect in NYHA classes III and IV heart failure.
Box Warnings: Tumorigenic in animal models
Briggs Pregnancy Recommendation: None
Common AEs (>10%):
- None known
Key Patient Counseling Points:
- May cause dizziness. Avoid driving, using machinery, or doing anything else that could be dangerous if not alert.
- Report signs/symptoms of hyperkalemia (muscle weakness, fatigue, bradycardia) and hyponatremia (confusion, dry mouth, thirst, weakness, hypotension, decreased urination).
- Avoid potassium supplements, foods/salt substitutes that are high in potassium
- Avoid alcohol and NSAIDs
Cozaar
Losartan Potassium
Main Indication: Antihypertensive
Therapeutic Classification: Angiotensin II Receptor Antagonist
FDA Labeled Indication:
1. HTN
2. Reduce risk of cerebrovascular accident, in hypertensive patients with left ventricular hypertrophy; prophylaxis, diabetic nephropathy
3. Diabetic nephropathy
MOA: A selective, reversible, competitive antagonist of the angiotensin II receptor (AT1), which is responsible for the physiologic effects of angiotensin II including vasoconstriction, aldosterone secretion, sympathetic outflow, and stimulation of renal sodium reabsorption
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): Headache
Key Patient Counseling Points:
- Avoid pregnancy
- Avoid sudden discontinuation; rebound HTN can occur - - Use potassium supplements or salt substitutes only under medical supervision
- May cause dizziness that may worsen if dehydrated
- Seek medical attention if angioedema, excessive fluid loss, hyperkalemia, reduction in urination, or jaundice occurs.
Avapro
Irbesartan
Main Indication: Antihypertensive
Therapeutic Classification: Angiotensin II Receptor Antagonist
FDA Labeled Indication:
1. Diabetic nephropathy in patients with diabetes mellitus type 2 and HTN
2. HTN
MOA: A selective, reversible, competitive antagonist of angiotensin II receptor (AT1), which is responsible for the physiologic effects of angiotensin II including vasoconstriction, aldosterone secretion, sympathetic outflow, and stimulation of renal sodium reabsorption.
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): Hyperkalemia
Key Patient Counseling Points:
- Seek medical attention if angioedema (swelling of the face, eyes, lips, tongue, or throat), excessive fluid loss (vomiting, diarrhea, or excessive perspiration), hyperkalemia (confusion, body weakness, uneven heartbeat, or numbness/tingling in hands or feet), reduction in urination, jaundice, or skin rash occurs
- Avoid pregnancy
- Avoid abrupt discontinuation
- Use potassium supplements or salt substitutes only under medical supervision
- This medicine may cause dizziness
- Avoid alcohol or driving
Benicar
Olmesartan
Main Indication: Antihypertensive
Therapeutic Classification: Angiotensin II Receptor Antagonist
FDA Labeled Indication:
1. HTN
Dosage Form (How Supplied): Tablet
MOA: A elective, reversible, competitive antagonist of the angiotensin II receptor.
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): None Known
Key Patient Counseling Points:
- Avoid pregnancy
- Use potassium supplements or salt substitutes only under medical supervision
- May cause dizziness that may worsen if dehydrated
- Seek care if angioedema, excessive fluid loss, hyperkalemia, reduction in urination, or jaundice occurs
- May cause orthostatic hypotension
Diovan
Valsartan
Main Indication: Antihypertensive
Therapeutic Classification: Angiotensin II Receptor Antagonist
FDA Labeled Indication:
1. HF
2. HTN
3. Acute coronary syndrome
MOA: A selective, reversible, competitive antagonist of the angiotensin II receptor, which is responsible for the physiologic effects of angiotensin II, including vasoconstriction, aldosterone secretion, sympathetic outflow, and stimulation of renal sodium reabsorption.
Box Warnings: Pregnancy
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%):
- Dizziness
- Increased BUN
Key Patient Counseling Points:
- Do not discontinue abruptly
- Use potassium supplements or salt substitutes only under medical supervision
- This medicine may cause dizziness
- Avoid driving, using machinery, or doing anything else that could be dangerous if not alert
- Recommend avoiding alcohol and NSAIDs while taking this drug.
Plavix
Clopidogrel Bisulfate
Main Indication: Hematological Agent
Therapeutic Classification: Platelet Aggregation Inhibitor/Glycoprotein IIB/IIIA Inhibitor
FDA Labeled Indication:
1. Acute STEMI (w/o PCI) and NSTEMI
2. Thrombosis prevention in arteriosclerotic vascular disease, following stroke, in peripheral arterial occlusive disease
MOA: An antiplatelet agent that prevents platelet aggregation by direct inhibition of ADP binding to receptor sites, inhibiting subsequent activation of the glycoprotein IIb/IIIa complex. This action is irreversible; therefore, platelets exposed to clopidogrel are inhibited for their lifespans
Box Warnings: Reduced CYP2C19 function
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Headache
Key Patient Counseling Points:
- Report signs/symptoms of bleeding, especially if used concomitantly with anticoagulant therapy
- Do not stop therapy abruptly without first talking with prescriber to minimize the risk of re-thrombosis, particularly after stent placement
Imdur
Isosorbide Mononitrate
Main Indication: Antianginal
Therapeutic Classification: Long-Acting Nitrate (Vasodilator)
FDA Labeled Indication: Angina, prophylaxis
Dosage Form (How Supplied):
Tablet ER, Tablet IR
MOA: The active 5-mononitrate metabolite of isosorbide dinitrate. Nitroglycerin and other organic nitrates are converted to NO by vascular endothelium. NO activates guanylate cyclase, increasing cyclic GMP that in turn decreases intracellular calcium, resulting in direct relaxation of vascular smooth muscle
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Dizziness, headache
Key Patient Counseling Points:
- Take medicine on an empty stomach with at least half a glass of water
- Swallow the extended-release tablet whole. Do not break, crush, or chew it.
- This medicine can cause headaches, which is a sign that the medicine is working. Acetaminophen may be used to relieve the headache. Contact HCP if headache is severe
- This medicine can cause dizziness
- Avoid driving, using machines, or doing anything else that could be dangerous if not alert
- Stand up slowly if this medicine causes light-headedness from orthostatic hypotension
- Do not stop using this medicine suddenly without consulting HCP. The dose may need to be slowly decreased before stopping it completely
- Avoid concomitant use of PDEIs as this may increase risk of severe hypotension
- Avoid drinking alcohol while taking this drug
- Scored tablets may be split. - Doses of immediate release formulation should be taken at least 7 h apart
Nitrostat, Nitroquick
Nitroglycerin
Main Indication: Antianginal
Therapeutic Classification: Nitrate Vasodilator
FDA Labeled Indication:
1. Angina, prophylaxis
2. Angina, acute
3. Anal fissure, chronic
Dosage Form (How Supplied): Capsule ER, SL Tablet, SL solution, Translingual Aerosol Solution, Transdermal Patch 24 h, Transdermal Ointment, Rectal Ointment
MOA: Believed to be converted to nitric oxide (NO) by vascular endothelium. NO activates guanylate cyclase, increasing cyclic GMP that in turn decreases intracellular calcium, resulting in direct relaxation of vascular smooth muscle. In myocardial ischemia, nitrates dilate large epicardial vessels, enhance collateral size and flow, and reduce coronary vasoconstriction.
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Headache
Key Patient Counseling Points:
- Sit prior to using sublingual tablets, lingual aerosol, or spray
- Tablet should be dissolved under tongue or in buccal pouch at first sign of angina; do not swallow or chew tablet
- Do not eat or drink after placement of tablets
- Spray should be sprayed onto or under tongue; do not inhale; do not spit out or rinse mouth after use.
- Rise slowly from a sitting position in order to prevent light-headedness
- Allow a 10- to 12-h/d drug-free interval to avoid development of nitrate tolerance for both patches and extended-release capsules
- Avoid concurrent use of alcohol, CNS depressants, antihypertensives, or other drugs that cause hypotension
- Do not use with PDEIs, which may result in hypotension
- The ointment may stain clothing
- When treating acute angina, instruct patient to call 911 if symptoms are not resolved by the first dose
Klor-Con, K-Dur, Micro-K
Potassium
Main Indication: Electrolyte
Therapeutic Classification: Electrolyte (Potassium supplement)
FDA Labeled Indication:
1. Hypokalalemia
2. Hypokalemia, prophylaxis
Dosage Form (How Supplied): Tablet, Extended Release; Capsule, Extended Release; Powder for Oral Solution; Solution
MOA: An electrolyte required for maintenance of the excitatory properties of neuromuscular tissues, and the resting membrane potential of cells is related to potassium concentrations, varying directly with the ratio of intracellular to extracellular potassium level
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%):
- Nausea
- Indigestion
- Flatulence
Key Patient Counseling Points:
- Take with food
- Take the powder, granule, or oral liquid only after mixing in 4 oz of water or juice
- Crush or break only specifically designed extended-release formulations
- Capsules may be opened, sprinkled on apple sauce, and ingested immediately
- Completely dissolve effervescent tablets in liquid and sip slowly over a 5-10 min period
Viagra, Revatio
Sildenafil
Main Indication: Vasodilator
Therapeutic Classification: PDE5 Inhibitor
FDA Labeled Indication:
1. Erectile dysfunction
2. Pulmonary HTN
Dosage Form (How Supplied): Tablet, Suspension
MOA: Inhibition of phosphodiesterase type 5 (PDE5) by sildenafil increases the amount of cyclic guanosine monophosphate (GMP) enhancing erectile function and pulmonary vasculature relaxation. Penile erection during sexual stimulation is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cyclic GMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum and vasodilation in the pulmonary bed.
Box Warnings: None
Briggs Pregnancy Recommendation: Limited human data—animal data suggest low risk
Common AEs (>10%): Flushing, nausea, headache, visual disturbances, lack of blue/green color discrimination
Key Patient Counseling Points:
- Take 30 min-4 h prior to anticipated sexual activity, but do not take more frequently than once q24h
Amoxil, Moxatag, Trimox
Amoxicillin
Main Indication: Antibiotic
Therapeutic Classification:
β-Lactam Antibiotic
FDA Labeled Indications:
• Acute otitis media
• Lower respiratory tract infection
• Streptococcal pharyngitis
• Ear, nose, throat, infection of skin and/or subcutaneous tissue, infection of genitourinary system
• H. Pylori
Dosage Form (How Supplied): Capsule, Chewable Tablet, Suspension, Tablet
MOA: Semisynthetic penicillin derivative that inhibits the biosynthesis of bacterial cell wall mucopeptide. Typically against Streptococcus, Enterococcus, Staphlococcus and Enterbacteriaciae.
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
Diarrhea, nausea
Key Patient Counseling Points:
• Complete full course of therapy
• For suspension, shake well and refrigerate. Note short expiration after reconstitution
• Can take with food to avoid upset stomach.
• Do not mix suspension w/ food or beverages and use with measuring device that comes with prescription.
• Symptoms should improve within 2 -3 days, seek HCP is it worsens
• May decrease effectiveness of oral contraceptives, encourage patients to use backup contraceptive method
Augmentin (XR)
Amoxicillin; Clavulanate Potassium
Main Indication: Antibiotic
Therapeutic Classification: β-Lactam Antibiotic
FDA Labeled Indications:
• Acute otitis media
• Community-acquired pneumonia
• Lower respiratory tract infection
• Sinusitis, infection of skin or subcutaneous tissue, infectious disease of genitourinary system
• UTI: acute cystitis + pyelonephritis
MOA: Amoxicillin is a semisynthetic penicillin derivative. Typically active against Streptococcus, Enterococcus, Staphylococcus, and Enterobacteriaceae. Amoxicillin is not effective against β-lactamase–producing bacteria. Clavulanate, a β-lactamase inhibitor, has weak antibacterial activity but is a potent inhibitor of plasmid-mediated β-lactamases and protects amoxicillin from degradation by β-lactamases.
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Nausea, diarrhea
Key Patient Counseling Points:
• Complete full course
• For suspension, shake well and refrigerate. Good for x 10 days.
• Can take with food to avoid upset stomach.
• Do not mix suspension w/ food or beverages.
• Symptoms should improve within 2 -3 days, seek HCP is it worsens
• May decrease effectiveness of oral contraceptives, encourage patients to use backup contraceptive method
Zithromax, Z-Pak
Azithromycin
Main Indication: Antibiotic
Therapeutic Classification: Macrolide antibiotic
FDA Labeled Indications:
• Acute infective exacerbation of COPD
• Skin or tissue infection
• Bacterial sinusitis
• Chancroid
• Nongonococcal cervicitis and urethritis
• CAP
• Sexually transmitted infections
• Streptococcal pharyngitis
MOA: Binds to the 50S ribosomal subunit, thus interfering w/ microbial protein synthesis. It is slightly less active when compared to Erythromycin against gram + bacteria but is substantially more active against M. (B.), Haemophilus sp., Legionella sp., Neisseria sp., Bordetella sp., Mycoplasma sp., and C. trachomatis.
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%): Diarrhea, nausea, vomiting
Key Patient Counseling Points:
• Complete full course
• Tablets be taken with or without food, but some pts report increased tolerance with food.
• Do not mix suspension w/ food or beverages, but food can be taken afterward
• Symptoms should improve within 2 -3 days, seek HCP is it worsens
Keflex, Daxbia
Cephalexin
Main Indication: Antibiotic
Therapeutic Classification: 1st-Generation Cephalosporin
FDA Labeled Indications:
• Infection of skin and/or SQ tissue infection
• Osteomyelitis
• OM
• Respiratory tract infection
• UTI
• Streptococcal pharyngitis
• Impetigo (skin infection)
• Ecthyma (deep impetigo)
• Cellulitis (nonpurulent)
• Erysipelas
MOA: Inhibits bacterial wall synthesis of actively dividing cells by binding to ≥ 1 PBPs. Most gram + bacteria, including non-penicillinase and penicillinase-producing staph and strep. Activity against gram - bacteria is less than what is observed with the 2nd and 3rd gen cephalosporins and is restricted for E. coli, Klebsiella, and Proteus mirabilis
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%): Nausea
Key Patient Counseling Points:
• Seek medical attention if rash develops
• Complete full course
• For suspension, shake well and refrigerate; has short expiration date
• Do not mix suspension w/ food or beverages, but food can be taken afterward.
• Symptoms should improve within 2 -3 days, seek HCP is it worsens
Omnicef
Cefdinir
Main Indication: Antibiotic
Therapeutic Classification: 3rd-Generation Cephalosporin
FDA Labeled Indications:
• Acute OM
• Pharyngitis
• Tonsillitis
• Bronchitis, acute, secondary bacterial infection
• Uncomplicated skin and/or SQ tissue infection
• CAP
• COPD, acute exacerbation
• Streptococcal pharyngitis, group A (alternative agent for mild, non-anaphylactic penicillin allergic)
Dosage Form (How Supplied): Suspension, Capsule
MOA: A 3rd-generation cephalosporin with activity against a number of gram-positive and gram-negative bacteria including β-lactamase–producing strains.
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%): Diarrhea
Key Patient Counseling Points:
• Complete full course
• For suspension, shake well and can be stored at room temp; Good for x 10 days.
• Do not mix suspension w/ food or beverages, but food can be taken afterward.
• Symptoms should improve within 2 -3 days, seek HCP is it worsens
• Separate administration of antacids, iron and vitamins by 2h
Levaquin
Levofloxacin
Main Indication: Antibiotic
Therapeutic Classification: Fluoroquinolone
FDA Labeled Indications:
• Bacterial prostatitis
• Bacterial sinusitis
• Bronchitis, chronic, acute bacterial exacerbation
• Community-acquired pneumonia
• Infection of skin and/or SQ tissue infection (uncomplicated)
• Pyelonephritis
MOA: Inhibits bacterial DNA gyrase, an enzyme responsible for the unwinding of DNA for transcription and subsequent supercoiling of DNA for packaging into chromosomal subunits. It is highly active against aerobic, gram-negative bacilli
Box Warnings:
Myasthenia gravis, tendon inflammation and rupture, peripheral neuropathy, CNS effects, cardiac, dermatologic and hypersensitivity reactions, aortic dissections and ruptures
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): Photosensitivity
Key Patient Counseling Points:
• Seek medical attention if decreased urination, yellowing of eyes, blistering skin rash or extreme fatigue, unusual bruising or bleeding SOB, chest pain, tendon pain, muscle weakness, "pins and needles" tingling or pricking sensation, numbness in the arms or legs, confusion or hallucinations.
• Take with or without food, but not with milk, yogurt, or other dairy products or calcium-fortified products (some juices and breads).
• If using antacids, sucralfate, or mineral supplements and multivitamins with calcium, iron, or zinc, take levofloxacin at least 2 h before or 6 h after these medicines.
Cipro
Ciprofloxacin
Main Indication: Antibiotic
Therapeutic Classification: Fluoroquinolone
FDA Labeled Indications:
• Anthrax, post exposure prophylaxis
• Bacterial prostatitis, chronic
• Bronchitis
• Lower respiratory tract infection
• Infection of bone, skin, or soft tissue, abdomen, sinusitis
• UTI
Dosage Form (How Supplied): Suspension, Tablet
MOA: Inhibits bacterial DNA gyrase. It is highly active against aerobic, gram-negative bacili.
Box Warnings: Serious adverse effects (tendon rupture, peripheral neuropathy, CNS), exacerbation of myasthenia gravis
Briggs Pregnancy Recommendation: Contraindicated
Common AEs (>10%): Tooth discoloration in infants, musculoskeletal signs and symptoms
Key Patient Counseling Points:
• Seek medical attention if decreased urination, yellowing of eyes, blistering skin rash or extreme fatigue, unusual bruising or bleeding SOB, chest pain, tendon pain, muscle weakness, "pins and needles" tingling or pricking sensation, numbness in the arms or legs, confusion or hallucinations.
• Take with or without food, but not with milk or other dairy products.
• Take cipro at least 2h before or 6h after antacids, sucralfate or mineral supplements and multivitamins with calcium, iron or zinc.
• If using suspension, shake well and can be stored at room temp
Cleocin
Clindamycin
Main Indication: Antibiotic
Therapeutic Classification: Lincosamide Antibiotic
FDA Labeled Indications:
• Bacterial infection disease, susceptible infections due to anaerobic organisms, staphylococci, streptococci, pneumococci
• Infection of skin and/or subcutaneous tissue
• Infectious disease of abdomen
• Lower respiratory tract infection
• Pelvic inflammatory disease
• Septicemia
• Osteomyelitis
• Diabetic foot infection
MOA: A semisynthetic 7-chloro-7-deoxylincomycin derivative that is active against most gram + organisms except enterocci and C diff.. Gram - aerobes are resistant, but most anaerobes are sensitive. It inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit; it is bactericidal or bacteriostatic depending on the concentration, organism and inoculums
Box Warnings: Colitis
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Nausea
Key Patient Counseling Points:
• Complete full course
• Symptoms should improve within 2 -3 days, seek HCP is it worsens
• Take with full glass of water
• Remain upright for 30 min after dose to minimize risk of GI ulceration
Vibramycin, Doxy 100
Doxycycline
Main Indication: Antibiotic
Therapeutic Classification: Tetracycline Antibiotic
FDA Labeled Indications:
• Acinetobacter infection
• Acne vulgaris
• Gonorrhea
• Staphylococcal infection of skin
• Pneumonia (community acquired)
Dosage Form (How Supplied): Suspension, tablet, delayed release tablet, capsule, delayed release capsule, syrup
MOA: A broad spectrum bacteriostatic compound that inhibits protein synthesis at the 30S ribosomal subunit. Activity includes gram + & -, aerobic and anaerobic bacteria as well as spirochetes, mycoplasmas, rickettsiae, chlamydiae and some protozoa. Many bacteria have developed plasmid-mediated resistance.
Box Warnings: None
Briggs Pregnancy Recommendation: Contraindicated, 2nd and 3rd Trimesters
Common AEs (>10%): Esophageal injury, photosensitivity, skin hyperpigmentation, tooth discoloration in children < 8 years of age
Key Patient Counseling Points:
• Do not take with food containing calcium
• Symptoms should improve within 2-3 days
• May cause photosensitivity; discontinue at first sign of skin erythema
• Wear sunscreen and avoid prolonged exposure to sunlight and UV light
• Administer with 240 mL of water
Bactroban
Mupirocin
Main Indication: Antibiotic
Therapeutic Classification:
Topical Antibacterial
FDA Labeled Indications:
• Impetigo
• Secondary skin infections
• Eradication of nasal colonization of MRSA during institutional outbreaks
Dosage Form (How Supplied): Topical Ointment, Topical Cream, Nasal Ointment
MOA: Inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Because of this unique mode of action, mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial agents (works against MRSA).
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
None known
Key Patient Counseling Points:
• Instruct patients on proper application technique. Avoid drug exposure to open wounds, burns, or eyes.
Flagyl
Metronidazole
Main Indication: Antibiotic
Therapeutic Classification:
Nitroimidazole antibiotic, antiprotozoal
FDA Labeled Indications:
• Abscess, anaerobic
• Amebic dysentery
• Bacterial vaginosis
• Trichomoniasis
MOA: A synthetic nitroimidazole active against T. vaginalis (trichomoniasis), E. histolytica (amebiasis), and G. lamblia (giardiasis); it is bactericidal against nearly all obligate anaerobic bacteria including B. fragilis.
Box Warnings: Carcinogenic
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
Headaches, nausea
Key Patient Counseling Points:
• Avoid alcohol while taking this medicine and for 3 d after, may cause severe disulfiram-like reaction.
• Complete full course of therapy. Symptoms should improve within 2-3 d; if they worsen, seek follow-up with HCP.
• May be administered with food to minimize stomach upset.
Extina, Ketozole, Nizoral, Nizoral A-d, Xolegel
Ketoconazole
Main Indication: Antifungal
Therapeutic Classification:
Imidazole Anti-fungal
FDA Labeled Indications:
• Candidiasis of skin
• Dandruff
• Pityriasis versicolor
• Seborrheic dermaitis
• Tinea corporis, cruris, and pedis
Dosage Form (How Supplied): Cream, Foam, Gel, Shampoo
MOA: Inhibits biosynthesis of ergosterol or other sterols, damaging the fungal cell wall membrane and altering its permeability
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
Application site reaction with foam
Key Patient Counseling Points:
• Apply thin layer to affected area of skin. Skin should be intact.
• Do not get it in your eyes, nose, mouth, or vagina.
• Do NOT wash the areas where you applied this medicine for at least 3 h after application.
• Cosmetics (makeup or sunscreens) may be put on the affected areas 20 min after application.
• Topical products are alcohol based and flammable immediately after application.
Diflucan
Fluconazole
Main Indication: Antibiotic
Therapeutic Classification:
Imidazole Anti-fungal
FDA Labeled Indications:
• Candidal vulvovaginitis, uncomplicated, and complicated
• Candidiasis, systemic
• Cryptococcal meningitis
• Oropharyngeal candidiasis
Dosage Form (How Supplied): Suspension, Tablet
MOA: Inhibits biosynthesis of ergosterol or other sterols, damaging the fungal cell wall membrane and altering its permeability
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
Headache
Key Patient Counseling Points:
• Many medications (including OTC) interact w/ flucanzole
• Do not take any new medications without consulting your doctor or pharmacist
• If taking weekly dose, take on same day and time each week
Zovirax
Acyclovir
Main Indication: Antiviral
Therapeutic Classification: Viral DNA Polymerase Inhibitor
FDA Labeled Indications:
• Genital Herpes simplex
• Herpes zoster (shingles)
• Varicella (chickenpox)
• Cold sores
Dosage Form (How Supplied): Capsule, Suspension, Tablet
MOA: An acyclic nucleoside analog of deoxyguanosine that is selectively phosphorylated by the virus-encoded thymidine kinase to its monophosphate form. Cellular enzymes then convert the monophosphate to the active antiviral acyclovir triphosphate, which competitively inhibits viral DNA synthesis by inactivation of viral DNA polymerase and incorporation into and termination of viral DNA replication. Acyclovir has potent activity against HSV I and II and HZV (VZV)
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%): Malaise
Key Patient Counseling Points:
• Complete full course
• Ensure adequate hydration
• For HSV, treatment should be started after the first sign of a lesion
• For VZV, treatment should begin within 24 h of rash
• Symptoms should improve within 2 -3 days, seek HCP is it worsens
• Medication will reduce the number of breakouts when used for prophylaxis or suppression of infection
Macrodantin, Macrobid
Nitrofurantoin
Main Indication: Antibactercidal
Therapeutic Classification: Nitrofuran Antibiotic
FDA Labeled Indications:
• UTI, treatment
• UTI, prophylaxis
MOA: Synthetic nitrofuran that inactivates bacterial ribosomes and is bactericidal in urine at therapeutic doses. It is active against most bacteria that cause UTIs except nearly all strains of Pseudomonas are resistant.
Box Warnings: None
Briggs Pregnancy Recommendation:
Human data suggest risk in 3rd trimester
Common AEs (>10%): Discoloration of urine
Key Patient Counseling Points:
• May make urine brown; this is not harmful and is a breakdown product of the drug
• Complete full course of therapy.
• For the suspension, shake well and store at room temperature, use within 30 d.
• Avoid mixing suspension with food or beverages; food can be taken afterward.
• Symptoms should improve within 2-3 days; if they worsen, seek follow-up care.
Bactrim, Septra
Sulfamethoxazole; Trimethoprim
Main Indication: Antibiotic
Therapeutic Classification: Sulfonamide Antibiotic
FDA Labeled Indications:
• Acute infective exacerbation of COPD
• HIV infection, Pneumocystis pneumonia
• HIV infection, Pneumocystis pneumonia, prophylaxis
• Traveler’s diarrhea
• UTI
Dosage Form (How Supplied):
Tablet, Suspension
MOA: SMZ competitively inhibits the synthesis of dihydropteroic acid (an inactive folic acid precursor) in microorganisms. TMP inhibits the enzymatic reduction of dihydrofolic acid to tetrahydrofolic acid. The combination is active against many bacteria and P. carinii. TMP/SMZ has in vitro activity against MRSA, but clinical success has been variable and unpredictable.
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%): Diarrhea, nausea
Key Patient Counseling Points:
• Complete full course of therapy
• For the suspension, shake well and store at room temperature and protect from light.
• Symptoms should improve within 2-3 d; if they worsen, seek follow-up with health-care practitioner
• May cause photosensitivity; use sunscreen.
• Maintain adequate hydration during therapy to prevent kidney complications.
• Seek medical attention for severe diarrhea, dark urine, yellowing of skin or eye, unusual bruising or bleeding, blistering skin rash, or shortness of breath.
Valtrex
Valacyclovir
Main Indication: Antiviral
Therapeutic Classification: Viral DNA Polymerase Inhibitor
FDA Labeled Indications:
• Genital Herpes simplex
• Herpes zoster (shingles)
• Varicella (chickenpox)
• Herpes labialis (Cold sore)
Dosage Form (How Supplied): Tablet
MOA: Valacyclovir is a prodrug of acyclovir. An acyclic nucleoside analog of deoxyguanosine that is selectively phosphorylated by the virus-encoded thymidine kinase to its monophosphate form. Cellular enzymes then convert the monophosphate to the active antiviral acyclovir triphosphate, which competitively inhibits viral DNA synthesis by inactivation of viral DNA polymerase and incorporation into and termination of viral DNA replication. Acyclovir has potent activity against HSV I and II and HZV (VZV)
Box Warnings: None
Briggs Pregnancy Recommendation: Compatible
Common AEs (>10%): Malaise, headache, nausea, neutropenia, nasopharyngitis, increased LFTs
Key Patient Counseling Points:
• Seek medical attention if decreased urination, unusual bruising or bleeding, blistering skin rash, or shortness of breath.
• Symptoms should improve within 2-3 d; if they worsen, seek follow-up with HCP.
• If using for prophylaxis, this medication should reduce the number of breakouts.
• Maintain adequate hydration during therapy to prevent renal complications.
Tamiflu
Oseltamivir Phosphate
Main Indication: Antibiotic
Therapeutic Classification:
Neuraminidase Inhibitor, Antiviral
FDA Labeled Indications:
• Influenza treatment and prophylaxis
Dosage Form (How Supplied): Capsule, Suspension
MOA: An inhibitor of influenza virus neuraminidase, which prevents viral progeny detaching from the cellular envelope
Box Warnings: None
Briggs Pregnancy Recommendation: N/A
Common AEs (>10%):
Nausea, vomiting, headache
Key Patient Counseling Points:
• Complete full course of therapy. Symptoms should improve within 2-3 d; if they worsen, seek care.
• Suspension is available in a 6 mg/mL concentration and is packaged with an oral syringe calibrated in milliliters up to a total of 10 mL. Instructions to the patient should be provided based on these units of measure (ie, mL).
• When providing oseltamivir suspension for children <1 y of age, use a lower volume (ie, <10 mL) oral syringe to ensure accurate dosing.
• If suspension unavailable, open capsules and compound a 6-mg/mL suspension.
• Take with food to minimize GI irritation.
• Take missed dose as soon as possible, if next dose is within 2 h, skip missed dose.